Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Accesswire
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Baird R W to a "strong-buy" rating.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Raymond James to a "strong-buy" rating.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $46.00 price target on the stock.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.MarketBeat
- Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
DYN
Earnings
- 11/12/24 - Miss
DYN
Sec Filings
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- 12/11/24 - Form 144
- DYN's page on the SEC website